Jeremy Levin's metamorphosis continues as Ovid's CEO
This article was originally published in Scrip
Jeremy Levin, the former CEO of Teva, is continuing his career transformation into biotech by taking up the position of chief executive officer at the private New York-based firm Ovid Therapeutics. Dr Levin was appointed Ovid's chairman last year and will continue to serve in this role.
You may also be interested in...
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.